Medicox

At a glance

Medicox filed 69 disclosures in the last 12 months, including 1 m&a. The most recent key filing was on Oct 15: A ₩8.5B deal, equal to 10.4% of total assets.

Revenue for 2025 was ₩28.2B, down 8% on 2024. It made an operating loss of ₩5.7B. Debt was 45% of equity at year end. The latest interim report (2026 H1) shows revenue of ₩12.8B and operating loss of ₩2.1B.

The 2025 annual report lists 58 employees with an average tenure of 5.7 years and average pay of ₩45.8M, #1922 of 2,191 listed companies by average pay. Its 12 directors and auditors were paid ₩36.1M each on average. It paid no cash dividend for 2025. 케이지 투자조합 and related parties held 16.89% at year end.

From the 2025 annual report

Staff: 58 (39 men, 19 women), of whom 6 on fixed-term contracts. Total pay for the year: ₩2.7B. Directors and auditors: 12, paid ₩433.6M in total.

No cash dividend was paid for 2025.

Largest shareholder

케이지 투자조합 holds 16.89%; with 0 related parties the group holds 16.89% of common shares at year end (from 0.00% at the start of the year).

Auditor: 삼일회계법인 · opinion: Disclaimer of opinion. The report includes an emphasis of matter.

Source: 2025 annual business report (DART). How figures are combined

Financial summary